RxDoctor Payments Data

Gregory Climaco, MD

Family Medicine · O'Fallon, ILNPI 1316034143

Payments from drug & device makers

$18,597in general payments, 2019–2025

Across 969 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$3K
  • AbbVie$3K
  • Lilly USA, LLC$1K
  • Johnson & Johnson$1K
  • Pfizer$813
  • plus $6K from 40 others

What the payments were for

  • Food & beverage$18,45299%
  • Education$1451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,597 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$147,571
Medicare patients
297
Services billed
2,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin333$359,535
OzempicSemaglutide188$254,412
FarxigaDapagliflozin Propanediol160$167,299
MounjaroTirzepatide72$139,733
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$48,436
OxycontinOxycodone Hcl13$45,318
EliquisApixaban48$41,185
VraylarCariprazine Hcl20$28,983
Breo ElliptaFluticasone/Vilanterol54$28,685
RybelsusSemaglutide22$25,815
Xigduo XrDapaglifloz Propaned/Metformin12$18,597
LinzessLinaclotide29$16,622
MovantikNaloxegol Oxalate31$14,561
InvokanaCanagliflozin11$14,213
SymbicortBudesonide/Formoterol Fumarate39$13,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$652$359,535333 claims
Novo NordiskOzempic, Rybelsus$3,112$280,227210 claims
AstraZenecaFarxiga, Symbicort$3,380$180,647199 claims
Lilly USA, LLCMounjaro$1,459$139,73372 claims
GSKTrelegy Ellipta, Breo Ellipta$521$77,120108 claims
AbbVieVraylar, Linzess$2,820$45,60549 claims
PfizerEliquis$813$41,18548 claims
Johnson & JohnsonInvokana, Xarelto$1,332$24,06622 claims
NovartisEntresto$100$5,88612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in O'Fallon

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →